25 research outputs found
Spread of malignant lymphoid cells into rat central nervous system with intact and disrupted blood–brain barrier
No full textQuiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia
No full textPharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
No full textBenefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials
No full textAntitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts
No full textPURPOSE: This study compared the antitumor activity and the pharmacological profile of gimatecan given orally and irinotecan (CPT-11) on pediatric tumor xenografts.
EXPERIMENTAL DESIGN: Gimatecan was tested in two neuroblastoma cell lines (SK-N-DZ and SK-N-(BE)2c) and on TE-671 rhabdomyosarcoma cells using two different schedules. We characterized its pharmacokinetic profile in nude mice bearing human SK-N-DZ and TE-671 cell lines.
RESULTS: Gimatecan appears to have high plasma disposition. The drug was present in plasma almost completely as the intact lactone form and showed substantial activity in all tumor models. Prolonged daily treatment with low doses of gimatecan produced significant tumor regression in all tumor xenografts.
CONCLUSION: The antitumor activity and the promising pharmacological profile indicate gimatecan as an excellent candidate for clinical treatment of pediatric tumors
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report
No full textMild orotic aciduria in UMPS heterozygotes: a metabolic finding without clinical consequences
No full textClinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate
No full text
